The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

15 articles for E Freire


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis and cholinesterase inhibition of cativic acid derivatives.EBI
Universidad Nacional Del Sur
Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.EBI
Kyoto Pharmaceutical University
Synthesis and biochemical evaluation of triazole/tetrazole-containing sulfonamides against thrombin and related serine proteases.EBI
The Johns Hopkins University
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening.EBI
Bryn Mawr College
Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.EBI
Kyoto Pharmaceutical University
Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.EBI
Kyoto Pharmaceutical University
Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.EBI
Kyoto Pharmaceutical University
Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function.EBI
University of Maryland
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.EBI
Kyoto Pharmaceutical University
A general strategy for creating "inactive-conformation" abl inhibitors.BDB
The Scripps Research Institute
Benzimidazole inhibitors of the sodium channelBDB
Degiacomo, Interim Trustee, Mark G.
Heteroaryl compounds and uses thereofBDB
Celgene Car
Ethynyl derivativesBDB
Hoffmann-La Roche
Benzamide derivativeBDB
Chugai Seiyaku Kabushiki Kaisha